Moreover, 68Ga- or 18F-labeled PSMA ligands enable the localization of tumor manifestations and thus help to differentiate between local, regional, and systemic disease in recurrent PC, which is crucial for subsequent treatment decisions. This evidence concerns the gene FOLH1 and pachyonychia congenita.